USP39 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | <1E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
4.31009672396954E-11 |
Normal-vs-Stage2 |
2.65600000004529E-06 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.043960E-03 |
Stage1-vs-Stage2 |
6.921400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.542000E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
8.188000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.62470037423645E-12 |
Normal-vs-AfricanAmerican |
1.066410E-01 |
Normal-vs-Asian |
1.260300E-02 |
Caucasian-vs-AfricanAmerican |
4.947800E-01 |
Caucasian-vs-Asian |
6.248800E-01 |
AfricanAmerican-vs-Asian |
7.515400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
7.88970000442646E-09 |
Normal-vs-Female |
5.06616970596951E-12 |
Male-vs-Female |
8.303400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
2.390100E-04 |
Normal-vs-Extreme_Weight |
2.76400013987654E-11 |
Normal-vs-Obese |
1.203690E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
8.728400E-01 |
Normal_Weight-vs-Obese |
3.532800E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
2.050200E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.725240E-01 |
Normal-vs-Age(41-60Yrs) |
7.34030000115737E-08 |
Normal-vs-Age(61-80Yrs) |
1.2989997966173E-10 |
Normal-vs-Age(81-100Yrs) |
2.158200E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.126000E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.447600E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.853000E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.653000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.272800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.995200E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
7.133800E-01 |
Normal-vs-Grade 3 |
8.584600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
1.334160E-01 |
Grade 2-vs-Grade 4 |
7.133800E-01 |
Grade 3-vs-Grade 4 |
8.584600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.44249065417534E-15 |
Normal-vs-N1 |
4.658900E-03 |
N0-vs-N1 |
1.981380E-01 |
|
|